[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352593-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352593-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","vascular-abnormalization-confers-tumor-resistance-to-antiangiogenic-therapy-via-downregulating-angiostatic-factors","Vascular abnormalization confers tumor resistance to antiangiogenic therapy via downregulating angiostatic factors","","Angiogenesis drives cancer progression, yet antiangiogenic therapy is limited by drug resistance whose mechanisms remain incompletely understood. Single cell clones derived from EO771 breast tumor cells were classified as resistant or sensitive to Anlotinib, then combined in orthotopic models to reveal antiangiogenic resistance pathways. Sensitive tumors showed more normalized vasculature and higher intratumoral CD8+ T cells, with vessel perfusion correlating with treatment response. RNA-seq identified dual-function genes linking angiostasis and immune activation, and adding angiostatic factors converted resistant tumors to sensitivity while neutralizing key angiostatic signals blocked responses.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/vascular-abnormalization-confers-tumor-resistance-to-antiangiogenic-therapy-via-downregulating-angiostatic-factors/352593/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/vascular-abnormalization-confers-tumor-resistance-to-antiangiogenic-therapy-via-downregulating-angiostatic-factors/352593.png","ImageObject",300,407,{"name":42,"@type":43},"\tJames","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main challenge addressed in the study?","Question",{"text":63,"@type":64},"The study addresses how antiangiogenic therapy efficacy is hindered by tumor resistance, where the underlying mechanisms are complex and multifactorial.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the researchers define sensitive versus resistant tumor clones?",{"text":68,"@type":64},"They established single cell clones from the EO771 breast tumor cell line and classified clones as resistant or sensitive to Anlotinib based on their responses.",{"name":70,"@type":61,"acceptedAnswer":71},"What factors influence Anlotinib efficacy according to the results?",{"text":72,"@type":64},"Sensitive clones showed more normalized vasculature, increased intratumoral CD8+ T cells, and better vessel perfusion, and RNA-seq revealed upregulated genes linking angiostasis with immune activation. Adding angiostatic factors converted resistant tumors to Anlotinib sensitivity, while neutralizing a key angiostatic factor impaired responses.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352593,1790762227,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336474466412,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Mao et al. Breast Cancer Research (2026) 28:59 Breast Cancer Research  \n[https://doi.org/10.1186/s13058-026-02229-4](https://doi.org/10.1186/s13058-026-02229-4)  \nRESEARCH Open Access  \nVascular abnormalization confers tumor resistance to antiangiogenic therapy via downregulating angiostatic factors  \nXunyuan Mao1,2,3,4,5†, Xiangyu Cao6†, Long Qian3, Meng Gao3, Naidong Zhang3,7, Mengmeng Huang1,3, Peng Fan3,7, Ziwei Qi3, Tingkun Liu3, Hongjie Zhang1* and Yuhui Huang2,3,4,5*  \nAbstract  \nBackground Angiogenesis is a hallmark of cancer. However, the efficacy of antiangiogenic therapy is hindered by drug resistance. The underlying mechanisms are complex and multifactorial, and the practical strategies to overcome resistance remain limited.  \nMethods By establishing single cell clones (SCCs) from EO771 breast tumor cell line, we classified SCCs as resistant and sensitive to Anlotinib, a new antiangiogenic agent. Resistant and sensitive SCCs were then mixed in different ways to uncover novel mechanisms of antiangiogenic resistance by integrating orthotopic tumor models, RNA sequencing (RNA-seq), immunohistochemistry, blocking antibodies, and recombinant proteins.  \nResults Increasing the diversity and quantity of sensitive SCCs overcame the influences of resistant SCCs and improved Anlotinib efficacy. Sensitive SCC tumors exhibited a more normalized vasculature and increased intratumoral CD8+ T cells compared to resistant SCC tumors. Moreover, elevated vessel perfusion was significantly correlated with better Anlotinib efficacy. RNA-seq data revealed upregulation of dual-function genes (e. g., Ifng, Cxcl9, and Vcam1) linking angiostasis and immune activation. Strikingly, the addition of an angiostatic factor (e. g., recombinant murine IFN-γ or Endostar) converted resistant breast tumors to sensitive to Anlotinib treatment and induced vascular normalization, whereas neutralizing IFNγ, a key angiostatic factor in sensitive SCC tumors, impeded their responses to Anlotinib.  \nConclusions The downregulation of angiostatic factors promotes breast tumor vascular abnormalization and resistance to antiangiogenic therapy. Therefore, integrating angiostatic factors with pro-angiogenic blockers may overcome resistance, offering a translatable approach to improve antiangiogenic outcomes in breast cancer. Keywords Angiostatic factors, Resistance, Antiangiogenic therapy, Vascular normalization, Tumor cell heterogeneity  \n†Xunyuan Mao and Xiangyu Cao have contributed equally to this work.  \n*Correspondence: Hongjie Zhang [hjzhang@um.edu. mo](hjzhang@um.edu. mo)[ ](hjzhang@um.edu. mo)Yuhui Huang [huangyh@suda.edu.cn](huangyh@suda.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nMao et al. Breast Cancer Research (2026) 28:59  \nIntroduction  \nTumor angiogenesis is a hallmark of cancer, which f","cbCaihg28HTYjBZT","https://ap.wps.com/l/cbCaihg28HTYjBZT","pdf",4260758,14,"English","# Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is the main challenge addressed in the study?\",\"answer\":\"The study addresses how antiangiogenic therapy efficacy is hindered by tumor resistance, where the underlying mechanisms are complex and multifactorial.\"},{\"question\":\"How did the researchers define sensitive versus resistant tumor clones?\",\"answer\":\"They established single cell clones from the EO771 breast tumor cell line and classified clones as resistant or sensitive to Anlotinib based on their responses.\"},{\"question\":\"What factors influence Anlotinib efficacy according to the results?\",\"answer\":\"Sensitive clones showed more normalized vasculature, increased intratumoral CD8+ T cells, and better vessel perfusion, and RNA-seq revealed upregulated genes linking angiostasis with immune activation. Adding angiostatic factors converted resistant tumors to Anlotinib sensitivity, while neutralizing a key angiostatic factor impaired responses.\"}]","Vascular abnormalization confers tumor resistance to antiangiogenic therapy via downregulating angiostatic factors | PDF",1790100392,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c76d2e977c9d7af1586cfa61434e36d.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a1efb5afde4259dd612d3b73b6742f3.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c921785d540a9b282448ae370a0e4931.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc96f6750d91f1c1e7196ee793034d59.webp",980,1306]